Total Payments
$2.3M
2024 Payments
$273,604
Companies
29
Transactions
2,047
Medicare Patients
1,369
Medicare Billing
$81,261
Payment Breakdown by Category
Other$1.3M (57.1%)
Consulting$578,821 (24.8%)
Travel$280,020 (12.0%)
Research$105,641 (4.5%)
Food & Beverage$36,982 (1.6%)
Education$112.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 392 | 57.0% |
| Consulting Fee | $578,821 | 137 | 24.8% |
| Travel and Lodging | $280,020 | 727 | 12.0% |
| Unspecified | $105,641 | 222 | 4.5% |
| Food and Beverage | $36,982 | 563 | 1.6% |
| Grant | $3,000 | 1 | 0.1% |
| Education | $112.00 | 5 | 0.0% |
Payments by Type
General
$2.2M
1,825 transactions
Research
$105,641
222 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $663,923 | 464 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $625,267 | 597 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $396,299 | 368 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $247,584 | 219 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $114,798 | 158 | $0 (2021) |
| Genentech USA, Inc. | $73,917 | 65 | $0 (2024) |
| GlaxoSmithKline, LLC. | $48,538 | 54 | $0 (2024) |
| AstraZeneca UK Limited | $31,353 | 14 | $0 (2023) |
| Amgen Inc. | $30,147 | 25 | $0 (2024) |
| Merck Sharp & Dohme LLC | $21,134 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $273,604 | 173 | GENZYME CORPORATION ($131,799) |
| 2023 | $256,051 | 193 | GENZYME CORPORATION ($139,971) |
| 2022 | $225,371 | 187 | GENZYME CORPORATION ($162,808) |
| 2021 | $154,878 | 121 | AstraZeneca Pharmaceuticals LP ($54,849) |
| 2020 | $161,860 | 119 | AstraZeneca Pharmaceuticals LP ($55,819) |
| 2019 | $554,017 | 537 | AstraZeneca Pharmaceuticals LP ($193,365) |
| 2018 | $422,784 | 397 | AstraZeneca Pharmaceuticals LP ($170,265) |
| 2017 | $287,438 | 320 | Teva Pharmaceuticals USA, Inc. ($182,210) |
All Payment Transactions
2,047 individual payment records from CMS Open Payments — Page 1 of 82
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,088.00 | General |
| 12/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,438.00 | General |
| Category: Immunology | ||||||
| 12/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,758.00 | General |
| Category: Immunology | ||||||
| 12/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $1,499.68 | General |
| Category: Immunology | ||||||
| 12/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $293.97 | General |
| Category: Immunology | ||||||
| 12/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $279.53 | General |
| Category: Immunology | ||||||
| 12/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $120.87 | General |
| Category: Immunology | ||||||
| 12/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | Cash or cash equivalent | $40.40 | General |
| Category: Immunology | ||||||
| 12/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $38.25 | General |
| Category: Immunology | ||||||
| 12/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | Cash or cash equivalent | $3.70 | General |
| Category: Immunology | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: Respiratory | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | Cash or cash equivalent | $122.66 | General |
| 11/01/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 10/30/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $477.09 | General |
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,438.00 | General |
| 10/28/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,010.00 | General |
| 10/26/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $141.62 | General |
| 10/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,758.00 | General |
| Category: Immunology | ||||||
| 10/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,758.00 | General |
| Category: Immunology | ||||||
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $723.35 | General |
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $208.11 | General |
| 10/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $123.92 | General |
| Category: Immunology | ||||||
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.38 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | Cash or cash equivalent | $7.67 | General |
| Category: Immunology | ||||||
| 10/24/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,438.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | SANOFI-AVENTIS U.S. LLC | $31,487 | 75 |
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma | SANOFI-AVENTIS U.S. LLC | $17,719 | 33 |
| Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study | GENZYME CORPORATION | $12,750 | 32 |
| A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma | SANOFI-AVENTIS U.S. LLC | $12,728 | 14 |
| A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | GENZYME CORPORATION | $9,286 | 21 |
| Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | GENZYME CORPORATION | $6,000 | 17 |
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma | GENZYME CORPORATION | $2,472 | 5 |
| ASP2b | SANOFI-AVENTIS U.S. LLC | $2,116 | 3 |
| A randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of duplilumab in patients with persistent asthma | SANOFI-AVENTIS U.S. LLC | $2,071 | 4 |
| A randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of duplilumab in patients with severe steroid dependent asthma | SANOFI-AVENTIS U.S. LLC | $1,984 | 3 |
| Expert consensus on SABA use for asthma clinical decision-making: a Delphi approach | Teva Pharmaceuticals USA, Inc. | $1,524 | 4 |
| An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma | SANOFI-AVENTIS U.S. LLC | $1,519 | 3 |
| US expert consensus on short-acting beta-agonist reliever medication use for asthma clinical decision-making: a mixed-method Delphi adjudication approach | Teva Pharmaceuticals USA, Inc. | $1,306 | 1 |
| US Expert Consensus On Short-acting Beta Agonist (SABA) Reliever Medication Use For Asthma Clinical Decision-making: A Mixed-method Delphi Adjudication Approach | Teva Pharmaceuticals USA, Inc. | $881.00 | 2 |
| A randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of dupilumab in patients with persistent asthma | GENZYME CORPORATION | $750.00 | 2 |
| A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma | GENZYME CORPORATION | $500.00 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma | GENZYME CORPORATION | $334.67 | 1 |
| A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dupilumab in patients with severe steroid dependent asthma | SANOFI-AVENTIS U.S. LLC | $213.06 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 706 | 783 | $147,177 | $25,790 |
| 2022 | 8 | 426 | 469 | $93,693 | $18,994 |
| 2021 | 3 | 134 | 201 | $60,033 | $20,819 |
| 2020 | 3 | 103 | 152 | $42,022 | $15,658 |
Total Patients
1,369
Total Services
1,605
Medicare Billing
$81,261
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 46 | 83 | $21,665 | $7,452 | 34.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 51 | 53 | $24,245 | $6,980 | 28.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 29 | 41 | $8,679 | $4,284 | 49.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 46 | $7,982 | $2,778 | 34.8% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 149 | 150 | $35,360 | $1,316 | 3.7% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 159 | 161 | $13,741 | $1,054 | 7.7% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 144 | 148 | $18,400 | $887.69 | 4.8% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 26 | 26 | $2,871 | $425.50 | 14.8% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 52 | 52 | $12,432 | $402.18 | 3.2% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2023 | 23 | 23 | $1,802 | $210.91 | 11.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 51 | 87 | $21,315 | $6,800 | 31.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 45 | 45 | $21,375 | $6,707 | 31.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 23 | 30 | $5,024 | $3,172 | 63.1% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 83 | 83 | $22,576 | $771.07 | 3.4% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 95 | 95 | $2,280 | $646.89 | 28.4% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2022 | 83 | 83 | $12,035 | $519.31 | 4.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 32 | 32 | $8,640 | $254.08 | 2.9% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2022 | 14 | 14 | $448.00 | $123.55 | 27.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 57 | 111 | $27,803 | $8,826 | 31.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 52 | 54 | $26,290 | $8,164 | 31.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 25 | 36 | $5,940 | $3,830 | 64.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 49 | 90 | $20,430 | $7,349 | 36.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 42 | 43 | $18,539 | $6,641 | 35.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 12 | 19 | $3,053 | $1,668 | 54.6% |
About Dr. Mario Castro, MD
Dr. Mario Castro, MD is a Critical Care Medicine healthcare provider based in Kansas City, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881610004.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mario Castro, MD has received a total of $2.3M in payments from pharmaceutical and medical device companies, with $273,604 received in 2024. These payments were reported across 2,047 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.3M).
As a Medicare-enrolled provider, Castro has provided services to 1,369 Medicare beneficiaries, totaling 1,605 services with total Medicare billing of $81,261. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Internal Medicine, Internal Medicine
- Location Kansas City, KS
- Active Since 07/14/2006
- Last Updated 11/08/2022
- Taxonomy Code 207LC0200X
- Entity Type Individual
- NPI Number 1881610004
Products in Payments
- FASENRA (Drug) $404,734
- DUPIXENT (Biological) $363,440
- CINQAIR (Drug) $271,146
- DUPIXENT (Drug) $209,511
- TEZSPIRE (Biological) $112,465
- CINQAIR (Biological) $84,924
- DUPIXENT DUPILUMAB INJECTION (Biological) $49,089
- BEVESPI AEROSPHERE (Drug) $29,721
- NUCALA (Biological) $29,345
- Xolair (Biological) $28,054
- NO PRODUCT DISCUSSED (Drug) $18,975
- ProAir Digihaler (Drug) $16,038
- RESLIZUMAB (Drug) $14,152
- AirDuo Digihaler (Drug) $7,807
- YUPELRI (Drug) $6,204
- ACTHAR (Biological) $5,694
- ALAIR (Device) $5,092
- GENERAL - BRONCHIAL THERMOPLASTY (Device) $4,038
- SPIRIVA (Drug) $2,180
- SPIRIVA RESPIMAT (Drug) $1,830
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Kansas City
Matthew Sharpe, M.d, M.D
Critical Care Medicine — Payments: $423,976
Critical Care Medicine $423,976
Harold Barkman, M.d, M.D
Critical Care Medicine — Payments: $97,847
Critical Care Medicine $97,847
Dr. Matthew Aboudara, M.d, M.D
Critical Care Medicine — Payments: $27,642
Critical Care Medicine $27,642
Dr. Robert Winfield, Md, MD
Critical Care Medicine — Payments: $12,986
Critical Care Medicine $12,986
Heath Latham, M.d, M.D
Critical Care Medicine — Payments: $9,676
Critical Care Medicine $9,676
Timothy Williamson, M.d, M.D
Critical Care Medicine — Payments: $8,096
Critical Care Medicine $8,096